[PDF][PDF] Variance stabilization applied to microarray data calibration and to the quantification of differential expression

W Huber, A Von Heydebreck, H Sültmann… - …, 2002 - researchgate.net
We introduce a statistical model for microarray gene expression data that comprises data
calibration, the quantification of differential expression, and the quantification of …

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

HL Kaufman, J Russell, O Hamid, S Bhatia… - The lancet …, 2016 - thelancet.com
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the …

R Pirker, JR Pereira, J Von Pawel, M Krzakowski… - The lancet …, 2012 - thelancet.com
Background Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study
showed that the addition of cetuximab to first-line chemotherapy significantly improved …

[HTML][HTML] Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

LY Dirix, I Takacs, G Jerusalem, P Nikolinakos… - Breast cancer research …, 2018 - Springer
Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have
shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this …

Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysis

V Brune, E Tiacci, I Pfeil, C Döring, S Eckerle… - The Journal of …, 2008 - rupress.org
The pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) and its
relationship to other lymphomas are largely unknown. This is partly because of the technical …

Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial

ML Disis, MH Taylor, K Kelly, JT Beck, M Gordon… - JAMA …, 2019 - jamanetwork.com
Importance Current treatment options for progressive ovarian cancer provide limited benefit,
particularly in patients whose disease has become resistant to platinum-based …

[HTML][HTML] Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 …

HL Kaufman, JS Russell, O Hamid, S Bhatia… - … for immunotherapy of …, 2018 - Springer
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial …

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

CR Heery, G O'Sullivan-Coyne, RA Madan… - The Lancet …, 2017 - thelancet.com
Summary Background Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody
that binds to PD-L1, inhibiting its binding to PD-1, which inactivates T cells. We aimed to …

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open …

JL Gulley, A Rajan, DR Spigel, N Iannotti… - The Lancet …, 2017 - thelancet.com
Summary Background Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and
approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown …

Parameter estimation for the calibration and variance stabilization of microarray data

W Huber, A von Heydebreck, H Sültmann… - … in genetics and …, 2003 - degruyter.com
We derive and validate an estimator for the parameters of a transformation for the joint
calibration (normalization) and variance stabilization of microarray intensity data. With this …